Clinical Determinants of Unintended Prolonged Opioid Use
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Researchers are trying to better understand how people who are prescribed opioids for short-term use, go on to receive this type of medication on a longer-term basis.
Condition or disease
Identify incident cases of UPOU and prospectively assess their characteristics in comparison to new opioid users who do not progress to UPOU. At each site, opioid-naïve adults who receive opioid prescriptions will be enrolled. Opioid prescriptions (both written and filled) and self-reported opioid use will be followed, and those subjects progressing to UPOU will be identified in real time. Matched samples of patients who do and do not develop UPOU will be recruited for assessment of framework elements related to patient characteristics,including biochemical confirmation of opioid use, pain-related measures (including psychological variables), and medical and social histories. Using the information gathered in Aim 1, structural equation modeling will be utilized to evaluate the associations UPOU and the patient domain.
Assess the rate of long-term opioid use [ Time Frame: Six months ]
At month 6 following the receipt of the initial opioid prescription, the status of opioid use will be assessed to determine the rate of converting to long-term use.
Secondary Outcome Measures :
Assess patient factors associated with development of long-term opioid use [ Time Frame: Six months ]
Patient factors potentially associated development of long-term opioid use will be assessed including depressive symptoms as measured using the Center for Epidemiological Studies-Depression Scale. Scores on the scale range from 0 to 60 where higher scores indicated greater levels of depression. A cut-off score of 27 or greater indicates clinically significant levels of depression.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Any individual that receives an opioid prescription.
Age ≥ 18 years
No use of opioids for 6 months prior to the issuance of the initial opioid prescription
Willingness to participate in all aspects of the study including use of the Hugo platform on their personal smartphone
Concurrent treatment for cancer (e.g., chemotherapy, radiation therapy)
Residence in an extended care facility
Any operation or hospitalization within the past 6 months
Mental health disorders that could impede functioning in an ambulatory care setting (e.g., schizophrenia, dementia)
Non-English speaking individuals
Use of a pharmacy that is not compatible with the Hugo platform.